GLPwatch
Papers (10409)
Page 126 of 174, ranked by citation count.
- The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity.
- Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development.
- Semaglutide, Ertugliflozin, and Deflazacort.
- Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
- Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
- Design of a novel long-acting dual GLP-1/GIP receptor agonist.
- Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
- Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.
- Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.
- Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
- Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system.
- Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024.
- Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
- Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
- Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend.
- Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.
- Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.
- [Acute pancreatitis in a patient treated with liraglutide].
- Dulaglutide reduces oxidative DNA damage and hypermethylation in the somatic cells of mice fed a high-energy diet by restoring redox balance, inflammatory responses, and DNA repair gene expressions.
- The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.
- Expression of NUCB2/nesfatin-1 in the taste buds of rats.
- Diabetes of Unclear Type in an Adolescent Boy With Multiple Islet-cell Autoantibody Positivity Successfully Managed With Glucagon-like Peptide-1 Receptor Agonist Alone: A Case Report.
- Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
- Fatty liver-induced changes in stereotypic behavior in rats and effects of glucagon-like peptide-1 analog on stereotypy.
- Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies.
- Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic.
- Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
- Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.
- Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide).
- Enhancing the Therapeutic Efficacy of GLP-1 for Hyperglycemia Treatment: Overcoming Barriers of Oral Gene Therapy with Taurocholic Acid-Conjugated Protamine Sulfate and Calcium Phosphate.
- Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran.
- Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
- Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
- Effect of exenatide on gastric emptying and graft survival in islet allograft recipients.
- New hypoglycemic agents and the kidney: what do the major trials tell us?
- Insulin release from isolated cat islets of Langerhans.
- Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
- Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment.
- Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway.
- Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.
- An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
- Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial.
- Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial.
- [Results of the LEADER study: current evidence and perspectives in research].
- A Case of Dulaglutide-Induced Vaginal Bleed.
- Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.
- Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
- The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
- Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
- Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
- Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.
- Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy <i>in vivo</i> and <i>in vitro</i>.
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Reply.
- Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
- Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
- Exploring omics signature in the cardiovascular response to semaglutide: Mechanistic insights and clinical implications.
- Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment.
- Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide.